oncolytic herpes simplex virus 2

Oncolytic herpes simplex virus 2 is a genetically engineered, replication-competent variant of human herpes simplex virus type 2 that selectively infects and lyses tumor cells while sparing normal cells. This process induces immunogenic cell death and stimulates both innate and adaptive antitumor immune responses through the release of tumor antigens and activation of immune cells including dendritic cells, natural killer cells, and CD8+ T cells. Some variants, such as OH2, include the deletion of neurovirulence genes (e.g., ICP34.5, ICP47) and insertion of genes encoding immune stimulatory molecules (e.g., GM-CSF), or expression of checkpoint blockade antibodies (e.g., anti-PD-1 in oHSV2-aPD1). The platform is being developed primarily as an investigational immunotherapy for various solid tumors, including metastatic ovarian cancer, advanced melanoma, and glioblastoma, both as monotherapy and in combination with checkpoint inhibitors[1][3][5].

Brand names

oHSV2-aPD1oHSV-2-aPD1oHSV 2-aPD1

Other names

oncolytic HSV2oHSV2oHSV-2oHSV 2OH2OH-2OH 2oHSV2-aPD1oHSV-2-aPD1oHSV 2-aPD1